Abstract
Efficacy of bortezomib and thalidomide in the recrudescent form of multicentric mixed-type Castleman's disease.
Highlights
A 16-year-old male patient was admitted to our hospital in March 2012 with chief complaints of systemic lymphadenopathy for 44 years with significant enlargement in the bilateral supraclavicular region for 1 month before admission
Bortezomib was given at the standard dose of 1.3 mg/m2 as an intravenous bolus on days 1, 4, 8 and 11, repeated at 21–28 days for a total of eight cycles; the chemotherapy consisted of the standard hyper-CVAD program that was given alternating hyper-CVAD with high-dose methotrexate and cytarabine for six cycles every 21–28 days
The serum IL-6, β2-microglobulin and C-reactive protein (CRP) level decreased to 11.3 pg/ml, 2.8 mg/l and 3.2 mg/l, respectively
Summary
A 16-year-old male patient was admitted to our hospital in March 2012 with chief complaints of systemic lymphadenopathy for 44 years with significant enlargement in the bilateral supraclavicular region for 1 month before admission. Biopsy of a left supraclavicular lymph node that was done in March 2008 at the first affiliated hospital of Zhengzhou University was suggestive of mixed-type Castleman's Disease. The patient was in good condition; lymphadenectasis and splenomegaly were unpalpable, and serum IL-6, β2-microglobulin and CRP levels decreased to 3.1 pg/ml, 1.9 mg/l and 2.4 mg/l, respectively.
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
